Oeser Steffen G, Rougee Luc R A, Collier Abby C
Pharmaceutical Sciences, 6609-2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Drug Metab Lett. 2015;9(2):88-98. doi: 10.2174/1872312809666150804111612.
Obesity in children is a significant clinical concern. There are many anecdotes and case studies regarding specific reactions of obese children to medications including therapeutic failure, adverse drug reactions and/or requirements for higher weight-adjusted dosing. There isis, however, a lack of basic and clinical data dissecting the mechanisms of these effects on pharmaceutical efficacy and safety. At present it is unknown how much of the difference in drug disposition in obese children can be attributed to obesity, to maturation or to an interaction between the two. Since a major determinant of drug disposition is hepatic metabolism, here we review how obesity alters hepatic drug disposition in children. Basic as well as clinical data summarizing the current knowledge of biochemical, physiological and clinical effects of pediatric obesity on drug disposition are considered. We conclude that there is a dire need for increased research into the direct effects of obesity on absorption, distribution, metabolism and excretion, as well as changes to pharmacokinetic parameters such as bioavailability and clearance. Increased effort in this area may elucidate the effects of obesity on clinical drug disposition with sufficient detail to provide better dosing guidelines where needed for children.
儿童肥胖是一个重大的临床问题。有许多关于肥胖儿童对药物的特定反应的轶事和案例研究,包括治疗失败、药物不良反应和/或更高体重调整剂量的需求。然而,缺乏剖析这些影响药物疗效和安全性机制的基础和临床数据。目前尚不清楚肥胖儿童药物处置的差异有多少可归因于肥胖、成熟或两者之间的相互作用。由于药物处置的一个主要决定因素是肝脏代谢,在此我们综述肥胖如何改变儿童的肝脏药物处置。考虑了总结儿科肥胖对药物处置的生化、生理和临床影响的现有知识的基础和临床数据。我们得出结论,迫切需要加强对肥胖对吸收、分布、代谢和排泄的直接影响以及生物利用度和清除率等药代动力学参数变化的研究。在这一领域加大努力可能会详细阐明肥胖对临床药物处置的影响,以便在需要时为儿童提供更好的给药指南。